Avycaz for Injection is unavailable as of August 8, 2016 and the shortage is estimated to last 6 months. The reason for the shortage according to the FDA Safety and Innovation Act (FDASIA) of 2012 ...

Allergan Plc said on Thursday the U.S. Food and Drug Administration had approved the drugmaker’s antibiotic Avycaz to treat two types of pneumonia caused by drug-resistant bacteria.

The agency first approved Avycaz in 2015 to treat adults with intra-abdominal infections in combination with metronidazole. In 2016, the FDA OK’d the antibiotic to treat complicated urinary ...

Allergan’s superbug antibiotic Avycaz raked in $22.1 million in sales during H1. But it will be slow going for the rest of 2016 because of an issue with its API maker delaying production ...

Avycaz was developed by Forest, another company which the M&A hungry Actavis acquired in 2014. Avycaz contains two drugs: ceftazidime, a previously approved cephalosporin antibacterial, and ...

Avycaz (ceftazidime-avibactam; Actavis) has been made available for the treatment of adult patients with complicated intra-abdominal infections (in combination with metronidazole) and complicated ...

Now, the company is adding a new antibiotic candidate to its pipeline through its acquisition of Arixa. If approved, the prospect could be the first new drug of its kind in more than 35 years.

Evidence of strong sales potential could entice other drugmakers to take up arms against so-called "superbugs," too--and Avycaz's strong early performance has come despite a $12,000 sticker price.

Allergan Plc said on Thursday the U.S. Food and Drug Administration had approved the drugmaker's antibiotic Avycaz to treat two types of pneumonia caused by drug-resistant bacteria.